Hepatopancreatoduodenectomy for Cholangiocarcinoma A Single-Center Review of 85 Consecutive Patients

被引:165
|
作者
Ebata, Tomoki
Yokoyama, Yukihiro
Igami, Tsuyoshi
Sugawara, Gen
Takahashi, Yu
Nimura, Yuji [2 ]
Nagino, Masato [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol,Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
关键词
cholangiocarcinoma; hepatopancreatoduodenectomy; BILE-DUCT CARCINOMA; AMERICAN JOINT COMMITTEE; MAJOR HEPATECTOMY; PORTAL-VEIN; PERIHILAR CHOLANGIOCARCINOMA; TUMOR CLASSIFICATION; SURGICAL-MANAGEMENT; BILIARY CANCER; RESECTION; PANCREATICODUODENECTOMY;
D O I
10.1097/SLA.0b013e31826029ca
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To outline our experience with hepatopancreatoduodenectomy (HPD) as a treatment for cholangiocarcinoma and to appraise the clinical significance of this challenging procedure. Background: Cholangiocarcinomas often exhibit an extensive ductal spread invading from the hepatic hilus to the lower bile duct, and such tumors can be completely resected only by HPD. Early experiences with HPD were associated with high mortality and morbidity, leading to an underestimation of the survival benefit of HPD. Methods: We retrospectively reviewed the medical records of 85 patients with cholangiocarcinoma who underwent HPD from 1992 to 2011. Major hepatectomy was performed in 79 patients (92.9%), and combined vascular resection was performed in 26 patients (30.6%). Results: The operating time was 762 +/- 141 minutes, and blood loss was 2696 +/- 1970 mL. Liver failure was the most common abdominal complication (n = 64), followed by pancreatic fistula (n = 60), wound sepsis (n = 33), intra-abdominal abscess (n = 22), refractory ascites (n = 17), bacteremia (n = 16), bile leakage (n = 13), and delayed gastric emptying (n = 12). Relaparotomy was necessary in 9 cases (11.1%). Overall, 19 patients (22.4%) exhibited Clavien grade 0 to II complications, 58 (68.2%) exhibited grade III, 6 (7.1%) exhibited grade IV, and 2 (2.4%) exhibited grade V (mortality). The overall survival rate for the 85 patients was 79.7% after 1 year, 48.5% after 3 years, 37.4% after 5 years, and 32.1% after 10 years; 9 (10.5%) patients survived for more than 5 years. The rate of survival for the 53 patients with pM0 disease who underwent R0 resection was the most favorable, with 5- and 10-year survival rates of 54.3% and 46.6%, respectively. Conclusions: HPD is technically demanding and is associated with high morbidity. However, this surgery can be performed with low mortality and offers a better probability of long-term survival in selected patients. As hepatobiliary surgeons, we should consider HPD to be a standard procedure for laterally advanced cholangiocarcinomas that are otherwise unresectable.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [1] Hepatopancreatoduodenectomy for advanced hepatobiliary malignancies: a single-center experience
    Dai, Wing Chiu
    Chok, Kenneth S. H.
    Cheung, Tan To
    Chan, Albert C. Y.
    Chan, See Ching
    Lo, Chung Mau
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2017, 16 (04) : 382 - 386
  • [2] Hepatopancreatoduodenectomy for advanced hepatobiliary malignancies:a single-center experience
    Wing Chiu Dai
    Kenneth SH Chok
    Tan To Cheung
    Albert CY Chan
    See Ching Chan
    Chung Mau Lo
    Hepatobiliary & Pancreatic Diseases International, 2017, 16 (04) : 382 - 386
  • [3] Evolution of Surgical Treatment for Perihilar Cholangiocarcinoma A Single-Center 34-Year Review of 574 Consecutive Resections
    Nagino, Masato
    Ebata, Tomoki
    Yokoyama, Yukihiro
    Igami, Tsuyoshi
    Sugawara, Gen
    Takahashi, Yu
    Nimura, Yuji
    ANNALS OF SURGERY, 2013, 258 (01) : 129 - 140
  • [4] Pathological aspects of mucinous cholangiocarcinoma: A single-center experience and systematic review
    Laohawetwanit, Thiyaphat
    Klaikaew, Naruemon
    PATHOLOGY INTERNATIONAL, 2020, 70 (09) : 661 - 670
  • [5] ESOPHAGOGASTRECTOMY - A CONSECUTIVE SINGLE-CENTER SERIES
    DEGARA, CJ
    PAYNEJAMES, JJ
    SILK, DBA
    MISIEWICZ, JJ
    MENZIESGOW, N
    HEPATO-GASTROENTEROLOGY, 1992, 39 (06) : 515 - 519
  • [6] A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma
    Pan, Ting-Ting
    Wang, Wei
    Jia, Wei-Dong
    Xu, Ge-Liang
    ONCOLOGY LETTERS, 2017, 13 (05) : 2957 - 2964
  • [7] A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma
    Pan, Ting-Ting
    Wang, Wei
    Jia, Wei-Dong
    Xu, Ge-Liang
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S76 - S76
  • [8] Liver transplantation in patients with incidental hepatocellular carcinoma/cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-center experience
    Elshamy, Mohammed
    Presser, Naftali
    Hammad, Abdulrahman Y.
    Firl, Daniel J.
    Coppa, Christopher
    Fung, John
    Aucejo, Federico N.
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2017, 16 (03) : 264 - 270
  • [9] Liver transplantation in patients with incidental hepatocellular carcinoma/cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-center experience
    Mohammed Elshamy
    Naftali Presser
    Abdulrahman Y Hammad
    Daniel J Firl
    Christopher Coppa
    John Fung
    Federico N Aucejo
    Hepatobiliary & Pancreatic Diseases International, 2017, 16 (03) : 264 - 270
  • [10] Percutaneous Nephrolithotomy Complications in 671 Consecutive Patients A Single-Center Experience
    Mousavi-Bahar, Seyed Habibollah
    Mehrabi, Sasan
    Moslemi, Mohammad Kazem
    UROLOGY JOURNAL, 2011, 8 (04) : 271 - 276